# A Phase 1 Dose-escalation Study of UGN-501 Administered Intravesically in Adult Participants With Recurrent NMIBC

> **NCT07725796** · PHASE1 · NOT_YET_RECRUITING · sponsor: **UroGen Pharma, Inc., a subsidiary of UroGen Pharma Ltd.** · enrollment: 30 (estimated)

## Conditions studied

- Bladder (Urothelial, Transitional Cell) Cancer
- NMIBC
- Urothelial Carcinoma Bladder
- Urothelial Carcinoma in Situ
- Urothelial Carcinoma Recurrent
- Urothelial Carcinoma of the Urinary Bladder
- Non-Muscle Invasive Bladder Carcinoma
- Non-muscle Invasive Bladder Cancer (NMIBC)

## Interventions

- **BIOLOGICAL:** UGN-501

## Key facts

- **NCT ID:** NCT07725796
- **Lead sponsor:** UroGen Pharma, Inc., a subsidiary of UroGen Pharma Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-09-30
- **Primary completion:** 2029-08-02
- **Final completion:** 2029-08-02
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-07-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07725796

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07725796, "A Phase 1 Dose-escalation Study of UGN-501 Administered Intravesically in Adult Participants With Recurrent NMIBC". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07725796. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*